JV between Leo Pharma and Klox Technologies

Canada-based Klox Technologies and Danish multinational Leo Pharma AS announced today they have created a JV in order to develop and commercialize novel and already existent products based on Klox’s Bio-Photonic portfolio, including Kleresca® for acne and Kleresca®. The new JV will be independently managed, led by Mikkel Schoedt, who was previously responsible for the Kleresca® Business Unit at LEO Pharma.
(Source: Leo Pharma)